VHB Lifesciences
VHB Lifesciences VHB Lifesciences
VHB Lifesciences VHB Lifesciences VHB Lifesciences VHB Lifesciences VHB Lifesciences VHB Lifesciences VHB Lifesciences VHB Lifesciences VHB Lifesciences
VHB Lifesciences VHB Lifesciences VHB Lifesciences VHB Lifesciences
VHB Lifesciences
api
VHB Lifesciences
VHB Lifesciences
Formulation
VHB Lifesciences
VHB Lifesciences
Field Force
VHB Lifesciences
VHB Lifesciences
VHB Lifesciences
Home » Product Index » Marketing Division » Proton
« Previous  1 | 2 | 3 | 4 | 5 | 6 | 7 | 8  Next »

Proton

We supply variety of oxaliplatin injection, doxorubicin hydrochloride injection, ifosfamide injection, amphotericin b injection, hydroxyurea capsules, dacarbazine injection etc.

XPLATIN

XPLATIN Generic Name :  Inj.Oxaliplatin

Packing :  Single Vial

Indication and dosage :
Early-stage colon cancer
Metastatic colorectal cancer
Recommended dose is 85 mg/m2 IV over two hours, on an every-two-week schedule. Can also administer 130 mg/m2 IV over six hours, on an every-three-week schedule

Therapeutic Segement :
Antineoplastic Agents

Our Brand Name :
XPLATIN

Strenghts :
50MG/25ML, 100MG/50ML

SOLOXAN

SOLOXAN Generic Name :  Inj.Ifosfamide with Mesna

Packing :  Single Vial

Indication and dosage :
Testicular cancer: 1,200 mg/m2 IV on days 1–5 every 21 days, as part of the VeIP salvage regimen.
Soft tissue sarcoma: 2,000 mg/m2 IV continuous infusion on days 1–3 every 21 days, as part of the MAID regimen.
Non-Hodgkin's lymphoma: 1,000 mg/m2 on days 1 and 2 every 28 days, as part of the ICE regimen.
Head and neck cancer: 1,000 mg/m2 on days 1–3 every 21–28 days, as part of the TIC regimen.

Therapeutic Segement :
Antineoplastic Agents

Our Brand Name :
SOLOXAN

Strenghts :
500MG combipack
1GM combipack
2GM combipack

ADROSOL ALSO AVAILABLE AS ADROSOL-RD

ADROSOL ALSO AVAILABLE AS ADROSOL-RD Generic Name :  Inj. Doxorubicin Hydrochloridenj.

Packing :  Single Vial

Indication and dosage :
Acute myelogenous leukemia—30 mg IV on days 1,2&3

Acute lymphoblastic leukemia—30 mg IV on days 1

Breast cancer-Doxorubicin 50mg\m2 IV on day 1 Repeat cycle every 21 days in AT Regimen

1.Single agent: 60–75 mg/m2 IV every three weeks.
2.Single agent: 15–20 mg/m2 IV weekly.
3.Combination therapy: 45–60 mg/m2 every three weeks.
4.Continuous infusion: 60–90 mg/m2 IV over 96 hours.

Therapeutic Segement :
Antineoplastic Agents

Our Brand Name :
ADROSOL ALSO AVAILABLE AS ADROSOL-RD

Strenghts :
10MG LYOPHILIZED VIAL
50MG LYOPHILIZED VIAL

MYCOL

MYCOL Generic Name :  Inj. Amphotericin B

Packing :  Single Vial

Indication and dosage :
Indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy

For adults and children is 5 mg/kg given as a single infusion. Should be administered by intravenous infusion at a rate of 2.5 mg/kg/h.

Therapeutic Segement :
Antineoplastic Agents

Our Brand Name :
MYCOL

Strenghts :
50 MG SINGLE VIAL

NEODREA

NEODREA Generic Name :  Cap. Hydroxyurea

Packing :  15*6 CAPSULES

Indication and dosage :
Chronic myelogenous leukemia.
Essential thrombocytosis.
Polycythemia vera.
Acute myelogenous leukemia, blast crisis
Head and neck cancer (in combination with radiation therapy)
Refractory ovarian cancer.

Continuous therapy: 20–30 mg/kg PO daily.
Intermittent therapy: 80 mg/kg PO every third day.
Combination therapy with irradiation of head and neck cancer: 80 mg/kg PO every third day.

Therapeutic Segement :
Antineoplastic Agents

Our Brand Name :
NEODREA

Strenght :
500 MG

ONCODAC

ONCODAC Generic Name :  Inj.Dacarbazine

Packing :  Single Vial

Indication and dosage :
Metastatic malignant melanoma.
Hodgkin's disease.
Soft tissue sarcomas.
Neuroblastoma.

1. Hodgkin's disease: 375 mg/m2 IV on days 1 and 15 every 28 days, as part of the ABVD regimen.Continuous therapy: 20–30 mg/kg PO daily.
2. Melanoma: 220 mg/m2 IV on days 1–3 and days 22–24 every 6 weeks, as part of the Dartmouth regimen. As a single agent, 250 mg/m2 IV for five days or 800–1,000 mg/m2 IV every three weeks.

Therapeutic Segement :
Antineoplastic Agents

Our Brand Name :
ONCODAC

Strenght :
100 MG SINGLE LYOPHILIZED VIAL
200 MG SINGLE LYOPHILIZED VIAL
500 MG SINGLE LYOPHILIZED VIAL

PLATIFIRST INJ

PLATIFIRST INJ Generic Name :  Inj. Cisplatin I.P

Packing :  Single Vial

Indication & Dosages :
Ovarian cancer: 75 mg/m2 IV on day one every 21 days
Testicular cancer: 20 mg/m2 IV on days 1–5 every 21 days
Head and neck cancer: 20 mg/m2/day IV continuous infusion for four days.
Non-small lung cancer: 60–100 mg/m2 IV on day one every 21 days
Bladder Cancer: 75mg/m2 IV on day 1.
Non Hodgkin's Lymphoma: 40mg/m2 IV on days 1,8 & 15

Therapeutic Segement :
Platinum analog

Our Brand Name :
PLATIFIRST INJ.

Strength :
PLATIFIRST INJ. 10MG & PLATIFIRST INJ. 50MG

NEOTAXL

NEOTAXL Generic Name :  Inj.Paclitaxel

Packing :  Single Vial

Indication & Dosages:
Ovarian cancer: 135–175 mg/m2 IV as a 3-hour infusion every three weeks.
Breast cancer: 175 mg/m2 IV as a 3-hour infusion every three weeks.
Bladder cancer, head and neck cancer: 250 mg/m2 IV as a 24-hour infusion every three weeks.

Non - small cell lung cancer.
Combination regimen:
175mg/m2 IV over 3 hours on day 1.Repeat cycle every 21 days.
Single - Agent regimens:80-100mg/m2 IV weekly for 3 weeks.

Esophageal cancer:
Combination regimen: 135mg/m2 IV for 24 hours on day 1 in adjuvant chemoyherapy. 200mg/m2 IV over 24 hours on day 1 in metastatic disease.
Sinle-Agent regimens: 250mg/m2 IV over 24 hours on day 1.

Therapeutic Segement :
Taxane, antimicrotubule agent

Our Brand Name :
NEOTAXL

Strength :
NEOTAXL 30MG/5ML,NEOTAXL 100MG/16.67ML,NEOTAXL 260MG/43.34ML,NEOTAXL 300MG/50ML & NEOTACL 250MG/